Press release
August 5, 2026
Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments
Sarepta Therapeutics, Inc. (SRPT)
New CEO Michael Severino, MD, brings extensive biopharma leadership and a proven track record of advancing innovation, building franchises, and delivering growth Net product revenues for the second quarter 2026 totaled $328.7 million, consisting of $230.6 million of PMO net product revenue and